<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851227</url>
  </required_header>
  <id_info>
    <org_study_id>087-CL-086</org_study_id>
    <nct_id>NCT00851227</nct_id>
  </id_info>
  <brief_title>Study to Compare Conivaptan in Subjects With Mild &amp; Moderate Liver Impairment Versus Subjects With Normal Liver Function</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and
      moderate liver impairment versus subjects with normal liver function
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure PK and protein binding of conivaptan</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure tolerability of conivaptan</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Liver Disease</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>1. Mildly Hepatic Impaired Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Moderately Hepatic Impaired Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Subjects with Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conivaptan hydrochloride</intervention_name>
    <description>intravenous</description>
    <arm_group_label>1. Mildly Hepatic Impaired Subjects</arm_group_label>
    <arm_group_label>2. Moderately Hepatic Impaired Subjects</arm_group_label>
    <arm_group_label>3. Subjects with Normal Hepatic Function</arm_group_label>
    <other_name>Vaprisol</other_name>
    <other_name>YM087</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Normal Hepatic Function:

               -  Weighs at least 45 kg

               -  Body mass index between 18 and 40 kg/m2 inclusive

               -  Must have normal hepatic function

          -  Hepatic Impaired Subjects:

               -  Weighs at least 45 kg

               -  Meets criteria for mild or moderate hepatic impairment defined by Child-Pugh
                  method

               -  Body mass index between 18 and 40 kg/m2 inclusive

        Exclusion Criteria:

          -  Subjects with Normal Hepatic Function:

               -  Smokes more than 10 cigarettes per day

               -  Known to be HIV positive or has HIV antibodies

               -  Has clinically significant history or presence of illness, malignancy, or
                  immunodeficiency

               -  Is Hepatitis A, B, or C positive

               -  Has had a blood transfusion or donated/lost more than 550ml of blood within 8
                  weeks of study drug administration

               -  History of substance abuse within 6 months prior to screening

          -  Hepatic Impaired Subjects:

               -  Has history or presence of biliary obstruction or biliary disease, hepatic
                  encephalopathy, advanced acidities, portal hypertension, or biliary liver
                  cirrhosis

               -  Is hypovolemic or has evidence of orthostatic hypotension

               -  Smokes more than 10 cigarettes per day

               -  Known to be HIV positive or has HIV antibodies

               -  Has clinically significant history or presence of illness, malignancy, or
                  immunodeficiency

               -  Has clinically significant history or presence of GI symptoms other than those
                  associated with moderate hepatic impairment

               -  Has had a blood transfusion or donated/lost more than 550ml of blood within 8
                  weeks of study drug administration

               -  History of substance abuse within 6 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Art Wheeler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cumberland Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=340</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Protein Binding</keyword>
  <keyword>Conivaptan</keyword>
  <keyword>Vaprisol</keyword>
  <keyword>Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

